Eye Diseases, Hereditary

3

Review clinical trials related to Eye Diseases, Hereditary. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13 of the USH2A gene. This is a multicenter study which will enroll approximately 81 participants, however, the exact number enrolled will depend on the final number completing the 24-month LUNA trial and are eligible and willing to enroll in CAPELLA.

Participants needed: 81
Trial details
Phase: Phase 2Age: 8+Biological sex: AllType: InterventionalSponsor: Laboratoires TheaUpdated: Sep 1, 2026
Eligibility criteria

Participants who have completed the LUNA study through Month 24 and, in the Inve... [+3]

Treatment Cohort only: New ocular condition in the SE (e.g., severe infection, u... [+5]

Status: Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.

Participants needed: 32
Trial details
Phase: Phase 3Age: 6+Biological sex: AllType: InterventionalSponsor: Laboratoires TheaUpdated: Jun 25, 2026Locations: 17
Eligibility criteria

Confirmed clinical diagnosis of LCA10 and a molecular diagnosis of homozygosity... [+4]

Mutations in genes other than the CEP290 gene associated with other IRD diseases... [+4]

Status: Recruiting

Inherited Retinal Degenerative Disease Registry

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.

Participants needed: 20,000
Trial details
Biological sex: AllType: ObservationalSponsor: Foundation Fighting BlindnessUpdated: May 19, 2026Locations: 1Duration: 20 Years
Eligibility criteria

Diagnosed with an inherited retinal degenerative disease OR

Glaucoma only [+3]